Analyzing Generics Market in Japan 2017
The development of the generic drugs sector in Japan has been a long standing plan of the Japanese government. The country has one of the highest healthcare costs amongst the G8 countries and the government has been focusing on developing the generics market in order to combat the rising healthcare and pharmaceutical costs. Due to this, the growth of the Japanese generics market does lag behind its peers countries.
Having experienced fluctuating growth in recent years, the Japanese generics industry has finally stabilized in terms of volume in the last year or so. The market's growth in terms of value is also expected to stabilize in the near future. The Japanese government plans to increase the share of the generics segment to nearly 80% of the total pharmaceutical market volume by the end of 2020.
Aruvian Research presents Analyzing Generics Market in Japan 2017 – a comprehensive coverage of the Japanese generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
Moving on, we analyze the Generics Industry in Asia Pacific through the same parameters.
The Generics Industry in Japan is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
We also include a Porter’s Five Forces analysis of the Japanese Generics Industry. Generics pricing and reimbursement situation in Japan and trends and challenges facing the industry are analyzed.
Analysis of the major industry players in the Japanese generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Daiichi Sankyo, Lupin, Sanofi SA, Teva Pharmaceutical Industries, Sawai Pharmaceutical Company and others. This concludes this comprehensive research report from Aruvian Research.
Having experienced fluctuating growth in recent years, the Japanese generics industry has finally stabilized in terms of volume in the last year or so. The market's growth in terms of value is also expected to stabilize in the near future. The Japanese government plans to increase the share of the generics segment to nearly 80% of the total pharmaceutical market volume by the end of 2020.
Aruvian Research presents Analyzing Generics Market in Japan 2017 – a comprehensive coverage of the Japanese generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
Moving on, we analyze the Generics Industry in Asia Pacific through the same parameters.
The Generics Industry in Japan is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
We also include a Porter’s Five Forces analysis of the Japanese Generics Industry. Generics pricing and reimbursement situation in Japan and trends and challenges facing the industry are analyzed.
Analysis of the major industry players in the Japanese generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Daiichi Sankyo, Lupin, Sanofi SA, Teva Pharmaceutical Industries, Sawai Pharmaceutical Company and others. This concludes this comprehensive research report from Aruvian Research.
A. EXECUTIVE SUMMARY
B. ANALYZING THE GLOBAL GENERICS INDUSTRY
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value & Volume Analysis
B.4 Industry Segmentation by Geography
B.5 Patent Expiries
B.6 Global Generic Industry Structure
B.7 Industry Forecast
C. GENERICS INDUSTRY IN ASIA PACIFIC
C.1 Industry Overview
C.2 Industry Value & Volume
C.3 Industry Segmentation by Geography
C.4 Industry Forecast
D. GENERICS INDUSTRY IN JAPAN
D.1 Industry Overview
D.2 Industry Value & Volume
D.3 Industry Segmentation by Geography
D.4 Regulatory Framework
D.5 Industry Forecast
E. GENERICS INDUSTRY IN JAPAN: PORTER’S FIVE FORCES STRATEGY ANALYSIS
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes
F. PRICING & REIMBURSEMENT IN JAPAN
F.1 Overview
F.2 Generics Pricing & Reimbursement Scenario
F.3 Trends & Challenges
G. MAJOR INDUSTRY PLAYERS
G.1 Allergan Plc
G.1.1 Corporate Analysis
G.1.2 Financial Analysis
G.1.3 SWOT Analysis
G.2 Daiichi Sankyo Co., Ltd.
G.2.1 Corporate Analysis
G.2.2 Financial Analysis
G.2.3 SWOT Analysis
G.3 Sanofi SA
G.3.1 Corporate Analysis
G.3.2 Financial Analysis
G.3.3 SWOT Analysis
G.4 Teva Pharmaceutical Industries Limited
G.4.1 Corporate Analysis
G.4.2 Financial Analysis
G.4.3 SWOT Analysis
G.5 Sawai Pharmaceutical Company Ltd
H. GLOSSARY OF TERMS
B. ANALYZING THE GLOBAL GENERICS INDUSTRY
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value & Volume Analysis
B.4 Industry Segmentation by Geography
B.5 Patent Expiries
B.6 Global Generic Industry Structure
B.7 Industry Forecast
C. GENERICS INDUSTRY IN ASIA PACIFIC
C.1 Industry Overview
C.2 Industry Value & Volume
C.3 Industry Segmentation by Geography
C.4 Industry Forecast
D. GENERICS INDUSTRY IN JAPAN
D.1 Industry Overview
D.2 Industry Value & Volume
D.3 Industry Segmentation by Geography
D.4 Regulatory Framework
D.5 Industry Forecast
E. GENERICS INDUSTRY IN JAPAN: PORTER’S FIVE FORCES STRATEGY ANALYSIS
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes
F. PRICING & REIMBURSEMENT IN JAPAN
F.1 Overview
F.2 Generics Pricing & Reimbursement Scenario
F.3 Trends & Challenges
G. MAJOR INDUSTRY PLAYERS
G.1 Allergan Plc
G.1.1 Corporate Analysis
G.1.2 Financial Analysis
G.1.3 SWOT Analysis
G.2 Daiichi Sankyo Co., Ltd.
G.2.1 Corporate Analysis
G.2.2 Financial Analysis
G.2.3 SWOT Analysis
G.3 Sanofi SA
G.3.1 Corporate Analysis
G.3.2 Financial Analysis
G.3.3 SWOT Analysis
G.4 Teva Pharmaceutical Industries Limited
G.4.1 Corporate Analysis
G.4.2 Financial Analysis
G.4.3 SWOT Analysis
G.5 Sawai Pharmaceutical Company Ltd
H. GLOSSARY OF TERMS
LIST OF FIGURES
Figure 1: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 2: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Figure 3: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Figure 4: Global Generics Market Segmentation by Geography (%), 2016
Figure 5: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
Figure 6: Market Share of Leading Generic Companies Worldwide (%), 2016
Figure 7: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
Figure 8: Global Generics Industry Forecast (in USD Billion), 2016-2021
Figure 9: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
Figure 10: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
Figure 11: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
Figure 12: Share of the Asia Pacific Generics Industry by Countries (%), 2016
Figure 13: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
Figure 14: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
Figure 15: Value of the Generics Market in Japan (in USD Billion), 2012-2016
Figure 16: Volume Growth of the Generics Market in Japan (%), 2012-2016
Figure 17: Share of Japan in the Asia Pacific Generics Industry (%), 2016
Figure 18: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Figure 19: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Figure 20: Porter's Five Forces Strategy Analysis of the Generics Industry in Japan
Figure 21: Bargaining Power of Buyers in the Japanese Generics Industry
Figure 22: Bargaining Power of Suppliers in the Japanese Generics Industry
Figure 23: Competitive Rivalry in the Japanese Generics Industry
Figure 24: Threat of New Entrants to the Japanese Generics Industry
Figure 25: Threat of Substitutes to the Japanese Generics Industry
Figure 26: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
Figure 27: Revenues & Profitability of Daiichi Sankyo (in USD Million), 2011-2015
Figure 28: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015
Figure 29: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
Figure 30: Revenues & Profitability of Sawai Pharmaceutical (in USD Million), 2011-2015
Figure 1: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 2: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Figure 3: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Figure 4: Global Generics Market Segmentation by Geography (%), 2016
Figure 5: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
Figure 6: Market Share of Leading Generic Companies Worldwide (%), 2016
Figure 7: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
Figure 8: Global Generics Industry Forecast (in USD Billion), 2016-2021
Figure 9: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
Figure 10: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
Figure 11: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
Figure 12: Share of the Asia Pacific Generics Industry by Countries (%), 2016
Figure 13: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
Figure 14: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
Figure 15: Value of the Generics Market in Japan (in USD Billion), 2012-2016
Figure 16: Volume Growth of the Generics Market in Japan (%), 2012-2016
Figure 17: Share of Japan in the Asia Pacific Generics Industry (%), 2016
Figure 18: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Figure 19: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Figure 20: Porter's Five Forces Strategy Analysis of the Generics Industry in Japan
Figure 21: Bargaining Power of Buyers in the Japanese Generics Industry
Figure 22: Bargaining Power of Suppliers in the Japanese Generics Industry
Figure 23: Competitive Rivalry in the Japanese Generics Industry
Figure 24: Threat of New Entrants to the Japanese Generics Industry
Figure 25: Threat of Substitutes to the Japanese Generics Industry
Figure 26: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
Figure 27: Revenues & Profitability of Daiichi Sankyo (in USD Million), 2011-2015
Figure 28: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015
Figure 29: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
Figure 30: Revenues & Profitability of Sawai Pharmaceutical (in USD Million), 2011-2015
LIST OF TABLES
Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
Table 4: Global Generics Industry Forecast (in USD Billion), 2016-2021
Table 5: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
Table 6: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
Table 7: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
Table 8: Share of the Asia Pacific Generics Industry by Countries (% & USD Billion), 2016
Table 9: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
Table 10: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
Table 11: Value of the Generics Market in India (in USD Billion), 2012-2016
Table 12: Volume Growth of the Generics Market in India (%), 2012-2016
Table 13: Share of India in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 14: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Table 15: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Table 16: Key Financials of Allergan Plc (in USD Million), 2011-2015
Table 17: Key Financials of Daiichi Sankyo (in USD Million), 2011-2015
Table 18: Key Financials of Sanofi SA (in USD Million), 2011-2015
Table 19: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
Table 20: Key Financials of Sawai Pharmaceutical (in USD Million), 2011-2015
Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
Table 4: Global Generics Industry Forecast (in USD Billion), 2016-2021
Table 5: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
Table 6: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
Table 7: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
Table 8: Share of the Asia Pacific Generics Industry by Countries (% & USD Billion), 2016
Table 9: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
Table 10: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
Table 11: Value of the Generics Market in India (in USD Billion), 2012-2016
Table 12: Volume Growth of the Generics Market in India (%), 2012-2016
Table 13: Share of India in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 14: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Table 15: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Table 16: Key Financials of Allergan Plc (in USD Million), 2011-2015
Table 17: Key Financials of Daiichi Sankyo (in USD Million), 2011-2015
Table 18: Key Financials of Sanofi SA (in USD Million), 2011-2015
Table 19: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
Table 20: Key Financials of Sawai Pharmaceutical (in USD Million), 2011-2015
